SML2075
Gimeracil
≥98% (HPLC)
别名:
5-Chloropyridine-2,4-diol, 5-chloro-4-hydroxypyridin-2(1H)-one, CDHP, Gimestat
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C5H4ClNO2
化学文摘社编号:
分子量:
145.54
UNSPSC Code:
12352200
NACRES:
NA.77
MDL number:
产品名称
Gimeracil, ≥98% (HPLC)
SMILES string
Clc1c[nH][c](cc1O)=O
InChI
1S/C5H4ClNO2/c6-3-2-7-5(9)1-4(3)8/h1-2H,(H2,7,8,9)
InChI key
ZPLQIPFOCGIIHV-UHFFFAOYSA-N
assay
≥98% (HPLC)
form
powder
color
white to brown
solubility
DMSO: 2 mg/mL, clear
storage temp.
−20°C
Biochem/physiol Actions
Gimeracil (5-chloro-2, 4-dihydroxypyridine) is an orally active inhibitor against dihydropyrimidine dehydrogenase (DPYD), which degrades pyrimidine and the chemotherapeutic drug 5-fluorouracil (5FU). Gimeracil is shown to exhibit cancer-radiosensitizing efficacy in cultures in vitro (1 mM) and in mice in vivo (2.5-25 mg/kg, p.o.) in a DPYD-dependent manner via partial suppression of DNA repair by homologous recombination (HR).
Orally active dihydropyrimidine dehydrogenase (DPYD) inhibitor with cancer-radiosensitizing efficacy in vitro and in vivo.
signalword
Warning
hcodes
Hazard Classifications
Acute Tox. 4 Oral
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Masakazu Fukushima et al.
Oncology reports, 24(5), 1307-1313 (2010-09-30)
Chemoradiotherapy is a useful treatment strategy in patients with locally advanced cancers. In particular, combination of 5-fluorouracil (5-FU) with X-ray irradiation is effective for the treatment of some types of gastrointestinal cancers. We investigated the antitumor effects of combination treatment
Keiji Koda et al.
Anticancer research, 36(10), 5325-5331 (2016-11-01)
It has not been elucidated whether the clinical efficacy of oral fluoropyrimidines for adjuvant chemotherapy of colorectal cancer varies with tumor biological characteristics. A multicenter randomized trial was performed comparing oral tegafur/gimeracil/oteracil (S-1) and uracil-tegafur/ leucovorin (UFT/LV) as adjuvant therapy
Ryohei Nishiguchi et al.
BMJ case reports, 2016 (2016-12-10)
The most common histological classification of bile duct cancer is adenocarcinoma and squamous cell carcinoma (SCC) is relatively rare. We report a case of a 78-year-old man with SCC of the extrahepatic bile duct associated with metachronous para-aortic lymph node
T Wang et al.
Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique, 20(3), 181-186 (2016-04-14)
This study evaluated the efficacy and safety of the combination drug tegafur, gimeracil, and oteracil potassium (S-1) concurrent with 3-dimensional conformal radiotherapy for newly diagnosed squamous cell carcinoma of the lung in elderly patients. Patients with pathologically or cytologically newly
Koh-Ichi Sakata et al.
Cancer science, 102(9), 1712-1716 (2011-06-15)
Gimeracil (5-chloro-2, 4-dihydroxypyridine) is an inhibitor of dihydropyrimidine dehydrogenase (DPYD), which degrades pyrimidine including 5-fluorouracil in the blood. Gimeracil was originally added to an oral fluoropyrimidine derivative S-1 to yield prolonged 5-fluorouracil concentrations in serum and tumor tissues. We have
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持